Medications
Brazil's Anvisa approved on Monday, February 2, 2026, the expansion of therapeutic indications for semaglutide, the active ingredient in Wegovy and Ozempic. Wegovy can now be used to reduce the risk of heart attacks and strokes in adults with cardiovascular disease and overweight, while Ozempic is indicated for type 2 diabetes associated with chronic kidney disease. The agency is also reviewing a request for an oral version of Wegovy.
Iniulat ng AI
Pharmaceutical company Gilead Sciences has signed a memorandum of understanding with Farmanguinhos, part of Fiocruz, to assess technology transfer and local production of lenacapavir, a semestral HIV prevention injection. The deal aims to lower costs and improve accessibility in Brazil, though it is not yet a formal commitment. Anvisa approved the drug on January 12, 2026.